Camizestrant significantly improved progression-free survival (PFS) compared to fulvestrant in patients with estrogen receptor (ER)-positive, HER2-negative breast cancer ... The objective response ...

The following is a summary of “Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage ...

Tizona Therapeutics has expanded its ongoing Phase Ib clinical trial of TTX-080, HLA-G, in patients with biomarker-defined ...

Inavolisib plus palbociclib-fulvestrant yields significantly longer progression-free survival than placebo plus ...

Vyloy plus standard-of-care chemotherapy extended overall survival in patients with advanced gastric cancer. The rate of ...

New research unveiled in the Journal of the National Comprehensive Cancer Network (JNCCN) highlights significant benefits of ...

There are many myths about breast cancer, particularly in Africa with its rich diversity of people, different genetic backgrounds and ancestral histories.

“Having a novel combination of well-tolerated medications significantly improving overall survival rates is terrific news for our patients here at Huntsman Cancer Institute and elsewhere.” By ...

The pancreatic cancer survival rate is one of the lowest of common cancers ... If you’re looking to prevent pancreatic cancer (or any other negative health outcomes), it’s always a good time to quit ...

This week’s recap highlights several significant FDA developments. We also cover ongoing successes of pembrolizumab with chemotherapy in NSCLC.

However, there is a concerning trend in the United States: the birth rate is going down. Experts also point out that advances in screening methods, such as 3-D mammograms, have improved cancer ...

There is, however, a greater risk of relapse and metastasis with a positive HER2 status, and survival rates are somewhat lower than for HER2-negative but estrogen receptor-positive tumors.